LeMaitre Vascular
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell LMAT and other ETFs, options, and stocks.About LMAT
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease.
CEOGeorge W. LeMaitre
CEOGeorge W. LeMaitre
Employees655
Employees655
HeadquartersBurlington, Massachusetts
HeadquartersBurlington, Massachusetts
Founded1983
Founded1983
Employees655
Employees655
LMAT Key Statistics
Market cap1.85B
Market cap1.85B
Price-Earnings ratio38.18
Price-Earnings ratio38.18
Dividend yield0.87%
Dividend yield0.87%
Average volume549.56K
Average volume549.56K
High today$82.72
High today$82.72
Low today$80.62
Low today$80.62
Open price$82.02
Open price$82.02
Volume48.50K
Volume48.50K
52 Week high$118.01
52 Week high$118.01
52 Week low$78.65
52 Week low$78.65
Stock Snapshot
The current LeMaitre Vascular(LMAT) stock price is $81.16, with a market capitalization of 1.85B. The stock trades at a price-to-earnings (P/E) ratio of 38.18 and offers a dividend yield of 0.87%.
During the trading session on 2026-08-11, LeMaitre Vascular(LMAT) shares reached a daily high of $82.72 and a low of $80.62. At a current price of $81.16, the stock is +0.7% higher than the low and still -1.9% under the high.
Trading volume for LeMaitre Vascular(LMAT) stock has reached 48.5K, versus its average volume of 549.56K.
The stock's 52-week range extends from a low of $78.65 to a high of $118.01.
The stock's 52-week range extends from a low of $78.65 to a high of $118.01.
LMAT News
Simply Wall St 1d
LeMaitre Vascular Has A Fresh Update, So Why Is It Drawing Attention? - simplywall.st...
Analyst ratings
50%
of 8 ratingsBuy
50%
Hold
50%
Sell
0%
People also own
Based on the portfolios of people who own LMAT. This list is generated using Robinhood data, and it’s not a recommendation.